Dosing and uses of Pamine, Pamine Forte (methscopolamine)
Adult dosage forms and strengths
tablet
- 2.5mg
- 5mg
Peptic Ulcer Disease
2.5 mg PO q8hr PC AND 2.5-5 mg PO qHS (4 daily doses)
May increase to 20 mg/day initial dose, no more than 30 mg/day
Administration
30 minutes before meals and bedtime
Pediatric dosage forms and strengths
tablet
- 2.5mg
- 5mg
Peptic Ulcer Disease (Off-label)
0.2 mg/kg/day OR 6 mg/sq.meter/day divided q8hr PO
Administration
30 minutes before meals & bedtime
Geriatric dosage forms and strengths
Peptic ulcer disease
2.5 mg PO q8hr PC AND 2.5-5 mg PO qHS (4 daily doses)
May increase to 20 mg/day initial dose, no more than 30 mg/day
Pamine, Pamine Forte (methscopolamine) adverse (side) effects
Frequency not defined
Allergic reaction
Blurred vision
Cycloplegia
Mydriasis
Headache
Dizziness
Drowsiness
Palpitation
Tachycardia
Nausea
Vomiting
Taste loss
Urinary retention
Warnings
Contraindications
Hypersensitivity to methscopolamine or related compounds
Closed-angle glaucoma, myasthenia gravis, hemorrhage with cardiovascular instability, paralytic ileus, intestinal atony of elderly/debilitated patient, obstructive uropathy, toxic megacolon, GI obstruction, tachycardia secondary to cardiac insufficiency or thyrotoxicosis
Cautions
Renal/hepatic impairment, BPH, CHF, CAD, HTN, COPD, hiatal hernia, reflux esophagitis, mitral stenosis, brain damage or spastic paralysis in children, salivary secretion disorder, Down synd, autonomic neuropathy, hyperthyroidism, tachyarrythmia, toxin-mediated diarrhea
Elderly (see Beers Criteria)
Risk of heat prostration in high environmental temperature
May produce drowsiness or blurred vision, caution if performing hazardous tasks
Use low dosage for patient with increased susceptibility to adverse antimuscarinic effects
Pregnancy and lactation
Pregnancy category: C
Lactation: not known if secreted in breast milk, use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Pamine, Pamine Forte (methscopolamine)
Mechanism of action
Reduces the volume of the total acid content of gastric secretion, reduces gastric secretion, and inhibits salivation. Peripherally blocks muscarinic receptors
Pharmacokinetics
Absorption: Incomplete
Onset of action: 1 hr
Duration: 4-6hr
Excretion: Urine, unabsorbed drug in feces
